| Document |
Document Title |
|
WO/2024/045950A1 |
Provided in the present invention are a steroid compound and a crystal form A thereof, and preparation methods therefor and the use thereof. The structure of the steroid compound is as shown in formula (II). An X-ray powder diffraction p...
|
|
WO/2024/037644A1 |
The present invention provides a polyethylene glycol (PEG)-modified glucocorticoid medicament and use thereof, including, but not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, rhinitis, and the like, and relates ...
|
|
WO/2024/036295A1 |
The disclosure relates to conjugates of the formulae (I) and (II): wherein the variables R1, R2, R3, R17, R18, R19, R20, R20A, R21, and G are defined herein, as well as methods for the use of the conjugates, and kits including the conjug...
|
|
WO/2023/241877A1 |
The present invention relates to a process for the preparation of a budesonide intermediate, in particular the compound of formula (I).
|
|
WO/2022/232602A9 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. These compounds are conjugates of glucocorticoids with rho-kinase inhibitors. Also provided herein are methods of t...
|
|
WO/2023/179721A1 |
The present invention provides a synthesis method for a 7-ketolithocholic acid or an intermediate thereof, which is prepared from a new intermediate I-1. According to the method, phytosterol degradation product bisnoralchol is used as a ...
|
|
WO/2023/158955A2 |
Disclosed are methods and oral compositions for treating CNS disorders. An embodiment of the invention comprises orally administering a 3α-OH-5β-pregnan-20-one containing composition to a subject having a CNS disorder. The composition ...
|
|
WO/2023/088308A1 |
A class of steroid derivatives, and a preparation method therefor, a pharmaceutical composition and the use thereof. The steroid derivative is represented by formula (I 0), and also comprises a hydrate, a solvate, an isotope derivative, ...
|
|
WO/2023/091930A1 |
The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutica...
|
|
WO/2023/079362A1 |
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment o...
|
|
WO/2023/035906A1 |
The present application provides an intermediate compound and a preparation method therefor and an application thereof. The intermediate compound has the following structural formula (I). By using the intermediate compound of the present...
|
|
WO/2023/023650A1 |
In one aspect, the disclosure relates to pregnane neurosteroid analogues of 5α-pregnan-3α-ol-20-one (3α,5α-THP). Also disclosed herein are methods of making the same, pharmaceutical compositions comprising the same, and methods of tr...
|
|
WO/2023/016817A1 |
The present invention is directed to a process for the preparation of ∆9,11 steroids by deoxygenation of 9,11-epoxy steroids using HI. The disclosed process selectively forms ∆9,11 steroids such as Vamorolone and can also be used for...
|
|
WO/2022/225999A1 |
Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administerin...
|
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/084752A1 |
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...
|
|
WO/2021/262040A1 |
The present invention relates to medicine and concerns the treatment of diseases associated with aberrant Interleukin-6 activity and the development of cytokine release (cytokine storm) syndrome, preferably the treatment of COVID-19, as ...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/220061A2 |
Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, b...
|
|
WO/2021/203938A1 |
The present invention relates to a compound for treating gout, a preparation method therefor and the use thereof. The compound is as represented by formula I. Disclosed in the present invention are a method for preparing the compound and...
|
|
WO/2021/203198A1 |
The present technology generally relates to the use of an asparaginase compound, and optionally of a chloroquine active agent and/or a serine protease inhibitor and/or a lectin, for inhibiting or treating a Coronaviridae infection in a s...
|
|
WO/2021/194244A1 |
The present invention relates to a novel method for preparing Inotodiol. The method differs in terms of process from existing methods for preparing Inotodiol, and produces a high yield of Inotodiol. Therefore, the method can be useful fo...
|
|
WO/2021/023213A1 |
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effect...
|
|
WO/2021/014217A1 |
The present invention is directed towards articles comprising a steroid material comprising a steroid dimer and at least one therapeutic agent distributed throughout the steroid material and the use of such articles in sustained release ...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/198878A1 |
The present application provides compounds, compositions and methods to reduce, alleviate or treat various enteric diseases and disorders, such as inflammatory bowel disease. The compounds are xyloglucan-containing prodrugs, referred to ...
|
|
WO/2020/191477A1 |
The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (lId): -L1...
|
|
WO/2020/185710A1 |
The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a neurosteroid GABAA positive allosteric modulator or pharmaceutically acceptable salt thereof to a subject ...
|
|
WO/2020/181395A1 |
The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase i...
|
|
WO/2020/161317A1 |
The present invention concerns a genetically modified bacterium and to its industrial application, in particular in the 1,2-dehydrogenation of steroids.
|
|
WO/2020/154815A1 |
The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21'-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said ...
|
|
WO/2020/020728A1 |
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...
|
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/148291A1 |
The disclosure features ocular inserts for the sustained release of steroids in the treatment ocular conditions. Said ocular inserts are articles formed from a compound of formula D1-L-D2 (A-I), wherein D1 and D2 are steroid radicals sel...
|
|
WO/2019/148294A1 |
Dimeric dexamethasone prodrugs (I) and articles formed from said dimeric dexamethasone prodrugs are disclosed. The articles comprising Dimeric dexamethasone prodrugs can be heat molded, injection molded, blow molded, electrospun, electro...
|
|
WO/2019/148293A1 |
Steroid dimers and articles formed from steroid dimers are disclosed. Said steroid dimers are represented by D1-L-D2 wherein D1 and D2 are steroid moieties and L is a covalent linker. The articles comprising the steroid dimers can be mac...
|
|
WO/2019/128154A1 |
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2018/164715A1 |
The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
|
|
WO/2018/037423A1 |
The present invention discloses a process for the preparation of pregnadiene derivatives having formula I, their stereoisomer and intermediate thereof. Formula I wherein each substituent is independently, R1 and R2 is hydrogen or C1 –C...
|
|
WO/2017/192668A1 |
Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based o...
|
|
WO/2017/153497A1 |
The invention provides a co-crystal, which co-crystal comprises beclomethasone dipropionate and a co-crystal former, which co-crystal former is adipic acid, maleic acid or isonicotinic acid. The invention also concerns a pharmaceutical c...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2017/106957A1 |
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.
|
|
WO/2017/037081A1 |
The present invention relates to new compounds of formula (1) wherein R is -C(=O)CH2OH or -CH(OH)CH2OH; R1, is =O or OH; R2 is H or OH; R3 is H or C1-C4alkyl; R4 is H or C1C4alkyl. These compounds are obtained by a process using at least...
|
|
WO/2016/123117A1 |
The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppre...
|
|
WO/2016/120891A1 |
The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula (I) wherein each substituent is independently selected from; R1 is H or CH3; R2 is C1-C6 linear or branched alkyl, alk...
|
|
WO/2016/055533A1 |
The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, ...
|
